Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

ZOSTAVAX Powder and solvent for suspension for injection (2020)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

ZOSTAVAX powder and solvent for suspension for injection. ZOSTAVAX powder and solvent for suspension for injection in a pre-filled syringe. shingles (herpes zoster) vaccine (live)

Qualitative and quantitative composition

After reconstitution, 1 dose (0.65 mL) contains: Varicella-zoster virus<sup>1</sup>, Oka/Merck strain, (live, attenuated) not less than 19,400 PFU<sup>2</sup>. 1 produced in human diploid (MRC-5) cells ...

Pharmaceutical form

Powder and solvent for suspension for injection. The powder is a white to off-white compact crystalline plug. The solvent is a clear, colourless fluid.

Therapeutic indications

ZOSTAVAX is indicated for prevention of herpes zoster (zoster or shingles) and herpes zoster-related post-herpetic neuralgia (PHN). ZOSTAVAX is indicated for immunization of individuals 50 years of age ...

Posology and method of administration

Posology Individuals should receive a single dose (0.65 mL). The need for a booster dose is not known. See sections 4.8 and 5.1. Paediatric population The safety and efficacy of ZOSTAVAX in children and ...

Contraindications

History of hypersensitivity to the active substance, to any of the excipients or trace residuals (e.g. neomycin) (see sections 4.4 and 6.1). Primary and acquired immunodeficiency states due to conditions ...

Special warnings and precautions for use

Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic/anaphylactoid reaction following the administration of the vaccine, as there is a possibility ...

Interaction with other medicinal products and other forms of interaction

ZOSTAVAX can be administered concomitantly with inactivated influenza vaccine as separate injections and at different body sites (see section 5.1). The concomitant use of ZOSTAVAX and a 23-valent pneumococcal ...

Fertility, pregnancy and lactation

Pregnancy There are no data on the use of ZOSTAVAX in pregnant women. Traditional non-clinical studies are insufficient with respect to reproductive toxicity (see section 5.3). However naturally-occurring ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive or use machines have been performed. However, ZOSTAVAX is expected to have no or negligible influence on ability to drive and use machines.

Undesirable effects

a. Summary of the safety profile The most common adverse reactions reported in pivotal clinical trials were injection-site reactions. Headache and pain in the extremity were the most common systemic adverse ...

Overdose

Administration of a higher than recommended dose of ZOSTAVAX was reported rarely and the adverse reaction profile was comparable to that observed with the recommended dose of ZOSTAVAX.

Pharmacodynamic properties

Pharmacotherapeutic group: Vaccines, Viral Vaccine ATC code: J07BK02 Mechanism of action Anyone who has been infected with VZV, including those without a clinical history of varicella, is at risk for developing ...

Pharmacokinetic properties

Not applicable.

Preclinical safety data

Traditional non-clinical studies were not performed, but there are no non-clinical concerns considered relevant to clinical safety beyond data included in other sections of the Summary of Product Characteristics ...

List of excipients

Powder: Sucrose Hydrolysed gelatin Sodium chloride Potassium dihydrogen phosphate Potassium chloride Monosodium L-glutamate monohydrate Disodium phosphate Sodium hydroxide (to adjust pH) Urea Solvent: ...

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 18 months. After reconstitution, the vaccine should be used immediately. However, in-use stability has been demonstrated for 30 minutes when stored at 20°C–25°C.

Special precautions for storage

Store and transport refrigerated (2°C–8°C). Do not freeze. Store in the original package in order to protect from light. For storage conditions after reconstitution of the medicinal product, see section ...

Nature and contents of container

ZOSTAVAX with solvent for reconstitution supplied in a vial: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (glass) with a stopper (chlorobutyl ...

Special precautions for disposal and other handling

Avoid contact with disinfectants as they may inactivate the vaccine virus. To reconstitute the vaccine, use the solvent provided. When reconstituted, ZOSTAVAX is a semi-hazy to translucent, off-white to ...

Marketing authorization holder

MSD VACCINS, 162 avenue Jean Jaurès, 69007, Lyon, France

Marketing authorization number(s)

EU/1/06/341/001 EU/1/06/341/002 EU/1/06/341/003 EU/1/06/341/004 EU/1/06/341/005 EU/1/06/341/006 EU/1/06/341/007 EU/1/06/341/008 EU/1/06/341/009 EU/1/06/341/010 EU/1/06/341/011 EU/1/06/341/012 EU/1/06/341/013 ...

Date of first authorization / renewal of the authorization

Date of first authorisation: 19 May 2006 Date of latest renewal: 11 February 2016

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: